{'output': [['Juniper Pharmaceuticals', 'COMP', 'Outline', 'Strategic Priorities For 2018', 'CONCEPT'], ['Juniper Pharmaceuticals', 'COMP', 'Report', 'Recent Portfolio Progress', 'CONCEPT'], ['Juniper Pharmaceuticals', 'COMP', 'Operate_In', 'Pharmaceuticals Industry', 'SECTOR'], ['Juniper Pharmaceuticals', 'COMP', 'Cash Flow Positive', 2018, 'ECON_INDICATOR'], ['Juniper Pharmaceuticals', 'COMP', 'Double-Digit Revenue Growth', 'Crinone and JPS', 'PRODUCT'], ['Juniper Pharmaceuticals', 'COMP', 'Discussion', 'Extend Crinone Progesterone Gel Agreement', 'EVENT'], ['Juniper Pharmaceuticals', 'COMP', 'Explore', 'Partnering Opportunities', 'CONCEPT'], ['Juniper Pharmaceuticals', 'COMP', 'Partnering Opportunities', 'JNP-0101', 'PRODUCT'], ['Juniper Pharmaceuticals', 'COMP', 'Partnering Opportunities', 'JNP-0301', 'PRODUCT'], ['Merck KGaA', 'COMP', 'Relate_To', 'Extend Crinone Progesterone Gel Agreement', 'EVENT'], ['Pharmaceuticals Industry', 'SECTOR', 'Include', 'Juniper Pharmaceuticals', 'COMP']]}